New York, New York–(Newsfile Corp. – July 31, 2023) – Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) NASDAQ: APLS. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Apellis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 15, 2023, the American Society of Retina Specialists issued a letter stating that physicians have reported multiple cases of eye inflammation in patients treated with Apellis’s drug Syfovre, approved in February for geographic atrophy.

On this news, Apellis’s stock price fell $32.04 per share, or 37.92%, to close at $52.46 per share on July 17, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/175541